Crude and type-specific incidence rates (A), all-cause mortality rates (B), and prevalence rates (C) of liver cancer per 100,000 over 2014–2023. حسب Ayana Ablayeva (22103708)

Crude and residence-specific incidence rates (A), all-cause mortality rates (B), and prevalence rates (C) of liver cancer per 100,000 over 2014–2023. حسب Ayana Ablayeva (22103708)

Comparison of rank correlation analysis results across groups of combinations - B1-B5 vs. C1-C10 vs. D1-D10. حسب Roman Vavrek (13200141)

Data Sheet 1_Cytotoxic CD4+ T-follicular cells may mediate killing against lymphoma cells.pdf حسب Yin Xiao (447102)

"…In this study, we aim to elucidate their presence and functional relevance in two different lymphoma subtypes, follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL). Flow cytometric analysis of tonsillar versus FL-cell suspensions revealed a heightened number of GZMK⁺NKG7/TIA-1⁺ T_F_K cells in the latter, accompanied by a significant increase in T-regulatory and T-follicular regulatory (T_FR) cells. …"

Age-adjusted annual percent changes (APC) in incidence (A), mortality (B), and prevalence (C) rates per 100,000 over 2014–2023 for both sexes and sex-specific. حسب Ayana Ablayeva (22103708)

The introduction of mutualisms into assembled communities increases their connectance and complexity while decreasing their richness. حسب Gui Araujo (22170819)

"…When they stop being introduced in further assembly events (i.e. introduced species do not carry any mutualistic interactions), their proportion slowly decreases with successive invasions. (B) Even though higher proportions of mutualism promote higher richness, introducing this type of interaction into already assembled large communities promotes a sudden drop in richness, while stopping mutualism promotes a slight boost in richness increase. …"

Comparison of agreement in the order based on the SD-TOPSIS technique across groups of combinations - B1-B5 vs. C1-C10 vs. D1-D10. حسب Roman Vavrek (13200141)

GS-1: Comparison of estimates of people for dataset A (left bar) and B (right bar) per region. Discrepancies occur in areas the Czech Republic and SE Germany. حسب Isabell Schmidt (6331013)

Factor associated with body fat mass loss^b'*' in both periods of inpatient treatment. حسب Domingos L. S. Rios (20496173)

Frequencies of IgM⁺ B cells, myeloid cells and CD8⁺ T cells of control and exposed brown trout in Wild, Wild:Farm and Farm groups. حسب Helena Saura Martinez (22305113)

Relative Index of Inequality (RII) and 95% Confidence Interval (CI) for access question between most a least deprived SIMD decile by A) Age and sex B) Number of Health Issues and c... حسب David Henderson (4612354)

Relative Index of Inequality (RII) and 95% Confidence Interval (CI) for overall satisfaction between most a least deprived SIMD decile by A) Age and sex B) Number of Health Issues... حسب David Henderson (4612354)

DataSheet1_Adverse childhood experiences, brain function, and psychiatric diagnoses in a large adult clinical cohort.pdf حسب David B. Keator (19842939)

Comparison of the regressor within the regression model of SD-TOPSIS technique results across groups of combinations - B1-B5 vs. C1-C10 vs. D1-D10. حسب Roman Vavrek (13200141)

Photomicrographs of H&E-stained cerebellum sections from control and different pregnant mothers: control (A & B) and BM (C & D) groups, showing normal histological structure of the... حسب Amoura M. Abou-El-Naga (21001524)

GI-1d-a: Comparison of estimates of people for dataset A (left bar) and B (right bar) per region. The largest discrepancies occur in areas of NE, SE and SW Germany and adjacent reg... حسب Isabell Schmidt (6331013)

Effect of supplementation of oocyte maturation medium (OMM) with follicular fluid (FF) from small or large follicles on development of embryos to the blastocyst stage. حسب Verónica M. Negrón-Pérez (20691412)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. حسب Elizabeth S. Munroe (21568166)

Antibody and antigen responses to Ensovibep vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. حسب Elizabeth S. Munroe (21568166)